Search

Your search keyword '"Pfeffer, Marc"' showing total 2,895 results

Search Constraints

Start Over You searched for: Author "Pfeffer, Marc" Remove constraint Author: "Pfeffer, Marc" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
2,895 results on '"Pfeffer, Marc"'

Search Results

1. Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial

2. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial

5. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

10. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.

11. Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial

12. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction

15. Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study

16. Abstract 12701: Safety and Tolerability of Angiotensin Receptor Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Drug Initiation Setting: A Subgroup Analysis of the PARADISE-MI Trial

17. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m2: Insights From PARAGON-HF and PARADIGM-HF

19. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib

22. Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial

23. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis

25. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial

26. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

33. Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease.

34. Cardiovascular‐kidney‐metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON‐HF.

35. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

36. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT

37. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

40. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial

45. Incidence and Outcomes of Pneumonia in Patients With Heart Failure

48. Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists:insight from the PARADISE MI trial

49. Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction:Insights from the PARADISE-MI Trial

Catalog

Books, media, physical & digital resources